Pembrolizumab
3475-992
Phase 3 small_molecule active
Quick answer
Pembrolizumab for Urinary Bladder Neoplasms is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Urinary Bladder Neoplasms
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active